Business News • PR NewsWire • Silence Therapeutics' Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting

Silence Therapeutics' Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting

Silence Therapeutics' Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting

LONDON, March 30, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") a leading global RNA interference (RNAi) therapeutics company, announces that interim data from its ongoing Phase I clinical study of Atu027, the Company's lead internal therapeutic candidate, hav

View More : http://www.prnewswire.com/news-releases/silence-therapeutics-phase-i-atu027-data-accepted-for-presentation-at-the-americ...

Releted News by prnewswire

Huscoke FY2010 Net Profit Jumped 81.46%

3 of 4 Online Users in New Zealand Watch Online Video

STMicroelectronics Named Again Among '350 Most Admired Companies' in FORTUNE Magazine's 2011 Annual Ranking

Benefits for Trade Recognised as Screwfix Celebrates Latest Win

Owens Corning Introduces Two New Grades of Short Glass Fiber Reinforcements for Polypropylene (PP)